Ophthalmic findings, in an effort to finding cures sooner and serving the patients, attach imperative to be on the cutting edge. The future of ophthalmology lies in the utilization of stem cells to promote tissue growth or gene therapy to introduce a gene via a viral vector to the target tissue for the treatment of eye diseases. Stem cells and gene therapy have real world applications for ophthalmic conditions. For an ophthalmology CRO, the notion of a new procedure or therapy must be explored and integrated into their strategy. Gene therapy is the future of ophthalmology for many diseases, and CRO’s need to remain on the cusp of innovation to help serve the patients and find cures.
In a field that is vastly growing and changing, the introduction of new methods of treatment will be on the forefront of many minds that make decisions and research new projects in the industry. In ophthalmology, gene therapy and stem cell research have enormous potential to be an alternative to treating eye disease and tissue loss.
Research in the field of ophthalmology can benefit from the notion of using gene therapy to promote or support tissue growth in problem areas of the eye. Dr. Elliot Sohn from the Department of Ophthalmology and Visual Sciences says on the subject of an ophthalmic research target: “For instance, it (gene and stem cell therapy) can replace a defective gene for inherited retinal disorders like retinitis pigmentosa and LCA, or it can provide key proteins needed to restore vision in more common diseases like AMD.” (Source)
The notion of gene therapy and stem cell research in the field of ophthalmology is still growing , but industry experts are commenting that these practices in the field are A CRO must be adaptable to changes in the industry. Communication and reporting frequency can change during the trial at the request of the sponsor. Contingency plans and proactive steps are taken to minimize the complexity in patient recruitment, IRB approval of protocols and informed consents,, delivery of stem cells and gene therapy technology from the manufacturing site to the bedside and quality.. The added complexity to study operations will require a sponsorto find a knowledgeable clinical contract research organization that is willing to operate on a flexible basis to complete the study.
Like the industry, it is imperative that an ophthalmology CRO like us stay on the cutting edge of their respective field. Trial Runners has developed a strategic approach to clinical research that maintains the focus of the program so that it stays within budget and on time.. In addition, Trial Runners has an extended record of being adaptable to all kinds of ophthalmic studies.
See how they can help in the growing field of ophthalmology here.